HealthTree Logo HealthTree Foundation
Donate
HealthTree Logo
Donate
Personal Health Record
  • My Feed
  • Recently viewed

Learn

  • Topics
  • Events

Explore

  • Find treatments & trials
  • Participate in research
  • Find a coach
  • Find a specialist
  • Talk to a patient navigator
  • Get involved
  • For researchers
  • For healthcare providers
  • About us
  • Get involved
  • For researchers
  • For healthcare providers
  • About us

Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Learn more about HealthTree
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Video

BETA - Can patients respond to a second line BCMA treatment? (2026 Updated)

Posted by
HealthTree Logo HealthTree
• February 27, 2026

Description

This video explains whether patients can respond to a second line BCMA treatment.

On this video

Healthtree contact Mohamad Mohty, MD, PHD

Mohamad Mohty, MD, PHD

Multiple Myeloma Specialist

Healthtree contact Natalie Callander, MD

Natalie Callander, MD

Multiple Myeloma Specialist

Related Content

  • News Can Mezigdomide Help Elranatamab Work Better? Early Results From the MELT-MM Trial
  • Video Etentamig for Relapsed Multiple Myeloma: New Bispecific Shows Strong Results, Low CRS | IMS 2026
  • News What Happens When Bispecific Antibodies Stop Working in Multiple Myeloma: Four Strategies to Overcome Resistance
  • Video Real-World Treatment Sequencing After CAR-T vs Bispecific Antibodies in Multiple Myeloma | EHA 2026
  • Video MajesTEC-9 Results : Teclistamab Outperforms PVd & Kd in Relapsed Myeloma: | EHA 2026